Literature DB >> 6488438

Synergistic antitumor activity of vincristine and VP-16-213.

D V Jackson, T R Long, T F Trahey, T M Morgan.   

Abstract

The potential interaction of the antitumor agents vincristine and VP-16-213 was investigated in vivo. DBA/2 mice were inoculated with 10(6) P388 murine leukemia cells, after which single IP injections of saline only, vincristine only, VP-16-213 only, or a combination of vincristine and VP-16-213 were administered. Long-term survival (greater than 60 days) was observed in 0/45, 1/45 (2%), 9/135 (7%), and 44/135 (33%) mice, respectively (P less than 0.001). Treatment was most effective when VP-16-213 was administered 0-72 h after vincristine. A similar trend was observed in mice bearing P1534 murine leukemia. These data demonstrate synergistic antitumor activity between vincristine and VP-16-213 in a murine model.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6488438     DOI： 10.1007/bf00269024

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  4 in total

1.  Combination chemotherapy with 4'Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-beta-D-glucopyranoside), VP 16-213 (NSC 141540) in L1210 leukemia.

Authors:  P Dombernowsky; N I Nissen
Journal:  Eur J Cancer       Date:  1976-03       Impact factor: 9.162

2.  Some pharmacologic properties of vincristine.

Authors:  R H Adamson; R L Dixon; B L Crews; S B Shohet; D P Rall
Journal:  Arch Int Pharmacodyn Ther       Date:  1965-10

3.  VP-16-213 (etoposide): the mandrake root from Issyk-Kul.

Authors:  N J Vogelzang; D Raghavan; B J Kennedy
Journal:  Am J Med       Date:  1982-01       Impact factor: 4.965

4.  Effect of VM-26 on the haematological responses of mice to L1210 leukaemia.

Authors:  M Hacker; D Roberts; C W Jackson
Journal:  Br J Cancer       Date:  1980-11       Impact factor: 7.640
  4 in total
  8 in total

Review 1.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

2.  Combination high-dose etoposide and vincristine infusion.

Authors:  D V Jackson; J M Cruz; D R White; H B Muss; A R Chauvenet
Journal:  Invest New Drugs       Date:  1990       Impact factor: 3.850

3.  VP-16, vincristine and procarbazine with radiation therapy for treatment of malignant brain tumors.

Authors:  R M Hellman; J A Calogero; B M Kaplan
Journal:  J Neurooncol       Date:  1990-04       Impact factor: 4.130

4.  A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas--an Eastern Cooperative Oncology Group Study (E2392).

Authors:  R Hellman; D S Neuberg; H Wagner; M Grunnet; H I Robins; D Karp; P Flynn; G Adams
Journal:  J Neurooncol       Date:  1998-03       Impact factor: 4.130

Review 5.  The clinical pharmacology of etoposide and teniposide.

Authors:  P I Clark; M L Slevin
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

6.  Etoposide-resistant human colon and lung adenocarcinoma cell lines exhibit sensitivity to homoharringtonine.

Authors:  L J Wilkoff; E A Dulmadge; G Vasanthakumar; J P Donahue
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Vincristine with high-dose etoposide in advanced breast cancer: a phase II trial of the Piedmont Oncology Association.

Authors:  G W Thomas; H B Muss; D V Jackson; J McCulloch; W Ramseur; J McFarland; H Hoen; M Pavy; R Heath
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Phase I study of vincristine and escalating doses of etoposide.

Authors:  D V Jackson; J M Cruz; P J Zekan; M E Caponera; C L Spurr; D R White; F Richards; H B Muss
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.